Fareston (toremifene) for metastatic breast cancer
July 1997
Schering is getting ready to market Fareston (toremifene) for metastatic breast cancer. It was just approved in the U.S...and is expected soon in Canada.
Fareston is the first estrogen antagonist to hit the market since Nolvadex (tamoxifen) came out 20 years ago.
Fareston is structurally very similar to Nolvadex.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive